Antares Pharma Inc.

3.80+0.0600+1.60%Vol 280.86K1Y Perf 40.71%
Sep 23rd, 2021 12:55 DELAYED
BID3.80 ASK3.81
Open3.75 Previous Close3.74
Pre-Market- After-Market-
 - -%  - -
Target Price
6.64 
Analyst Rating
Strong Buy 1.00
Potential %
76.13 
Finscreener Ranking
★★★★★     62.89
Insiders Trans % 3/6/12 mo.
-100/-100/-90 
Value Ranking
★★★★     57.08
Insiders Value % 3/6/12 mo.
-100/-100/-98 
Growth Ranking
★★★★★     81.89
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-97 
Income Ranking
 —    -
Price Range Ratio 52W %
47.95 
Earnings Rating
Sell
Market Cap645.88M 
Earnings Date
4th Nov 2021
Alpha0.01 Standard Deviation0.16
Beta1.48 

Today's Price Range

3.733.81

52W Range

2.635.07

5 Year PE Ratio Range

-65.00-11.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.60%
1 Month
-5.32%
3 Months
-13.82%
6 Months
-10.10%
1 Year
40.71%
3 Years
14.72%
5 Years
125.30%
10 Years
67.71%

TickerPriceChg.Chg.%
ATRS3.800.06001.60
AAPL146.730.88000.60
GOOG2 840.0021.23000.75
MSFT299.871.29000.43
XOM57.101.89003.42
WFC48.020.94002.00
JNJ165.611.68001.02
FB346.283.07000.89
GE103.534.99005.06
JPM161.235.32003.41
Financial StrengthValueIndustryS&P 500US Markets
1.50
1.80
0.06
0.24
6.20
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
60.00
14.00
15.90
-16.50
39.20
RevenueValueIndustryS&P 500US Markets
171.20M
1.01
38.97
29.09
Earnings HistoryEstimateReportedSurprise %
Q02 20210.020.0350.00
Q01 20210.020.020.00
Q04 20200.040.03-25.00
Q03 20200.030.030.00
Q02 2020-0.010.01200.00
Q01 20200.00-0.01-
Q04 20190.000.03-
Q03 2019-0.020.01150.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR0.03-25.00Negative
12/2021 QR0.030.00-
12/2021 FY0.110.00-
12/2022 FY0.22-12.00Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report0.03
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume280.86K
Shares Outstanding169.97M
Shares Float166.57M
Trades Count1.25K
Dollar Volume7.62M
Avg. Volume952.81K
Avg. Weekly Volume682.15K
Avg. Monthly Volume568.78K
Avg. Quarterly Volume659.72K

Antares Pharma Inc. (NASDAQ: ATRS) stock closed at 3.74 per share at the end of the most recent trading day (a 1.08% change compared to the prior day closing price) with a volume of 466.17K shares and market capitalization of 645.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 178 people. Antares Pharma Inc. CEO is Robert F. Apple.

The one-year performance of Antares Pharma Inc. stock is 40.71%, while year-to-date (YTD) performance is -6.27%. ATRS stock has a five-year performance of 125.3%. Its 52-week range is between 2.63 and 5.07, which gives ATRS stock a 52-week price range ratio of 47.95%

Antares Pharma Inc. currently has a PE ratio of 9.80, a price-to-book (PB) ratio of 4.81, a price-to-sale (PS) ratio of 3.64, a price to cashflow ratio of 31.90, a PEG ratio of 2.32, a ROA of 37.43%, a ROC of 52.53% and a ROE of 70.70%. The company’s profit margin is 39.20%, its EBITDA margin is 15.90%, and its revenue ttm is $171.20 Million , which makes it $1.01 revenue per share.

Of the last four earnings reports from Antares Pharma Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.03 for the next earnings report. Antares Pharma Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Antares Pharma Inc. is Strong Buy (1), with a target price of $6.64, which is +76.13% compared to the current price. The earnings rating for Antares Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Antares Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Antares Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.96, ATR14 : 0.12, CCI20 : -41.87, Chaikin Money Flow : -0.10, MACD : -0.09, Money Flow Index : 35.03, ROC : -4.59, RSI : 43.80, STOCH (14,3) : 45.24, STOCH RSI : 1.00, UO : 48.37, Williams %R : -54.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Antares Pharma Inc. in the last 12-months were: Anton G. Gueth (Option Excercise at a value of $187 031), Anton G. Gueth (Sold 100 000 shares of value $429 000 ), Fred M. Powell (Buy at a value of $46 740), Leonard S. Jacob (Option Excercise at a value of $68 638), Leonard S. Jacob (Sold 30 642 shares of value $154 742 ), Peter J. Graham (Option Excercise at a value of $50 400), Peter J. Graham (Sold 45 000 shares of value $221 650 ), Robert F. Apple (Option Excercise at a value of $470 210), Robert F. Apple (Sold 587 460 shares of value $2 913 603 ), Thomas J. Garrity (Option Excercise at a value of $425 600), Thomas J. Garrity (Sold 340 000 shares of value $1 457 800 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Antares Pharma Inc.

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

CEO: Robert F. Apple

Telephone: +1 609 359-3020

Address: 100 Princeton South, Ewing 08628, NJ, US

Number of employees: 178

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

Bearish Bullish

73%28%

News

Stocktwits